Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

THRD

Third Harmonic Bio Inc

Apr 19 • 09:53AM ET

11.92

Dollar change +0.49
Percentage change 4.29	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWN VXF IBB SCHA VTWO IWC VTWV RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.95	Insider Own	61.38%	Shs Outstand	40.10M	Perf Week	3.47%
Market Cap	485.26M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	-0.13%	Shs Float	15.73M	Perf Month	28.73%
Income	-30.82M	PEG	-	EPS next Q	-0.31	Inst Own	43.17%	Short Float	4.34%	Perf Quarter	22.76%
Sales	0.00M	P/S	-	EPS this Y	-68.92%	Inst Trans	-	Short Ratio	5.14	Perf Half Y	86.25%
Book/sh	6.71	P/B	1.78	EPS next Y	-28.37%	ROA	-10.70%	Short Interest	0.68M	Perf Year	167.87%
Cash/sh	6.61	P/C	1.80	EPS next 5Y	-	ROE	-11.05%	52W Range	4.06 - 12.42	Perf YTD	8.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.32%	52W High	-4.03%	Beta	2.76
Dividend TTM	-	Quick Ratio	50.29	Sales past 5Y	0.00%	Gross Margin	-	52W Low	193.60%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	50.29	EPS Y/Y TTM	-5.40%	Oper. Margin	0.00%	RSI (14)	66.09	Volatility	6.46% 7.46%
Employees	30	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	9.55
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	41.33%	Payout	-	Rel Volume	2.02	Prev Close	11.43
Sales Surprise	-	EPS Surprise	44.90%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	132.74K	Price	11.92
SMA20	15.90%	SMA50	19.86%	SMA200	46.87%	Trades		Volume	28,425	Change	4.29%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-22	Downgrade	Jefferies	Buy → Hold	$30 → $3.60
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Oct-10-22	Initiated	Morgan Stanley	Overweight	$34
Oct-10-22	Initiated	Jefferies	Buy	$30
Oct-10-22	Initiated	Cowen	Outperform

Apr-15-24 07:00PM	Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares (GuruFocus.com)
Mar-28-24 08:30AM	Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors (GlobeNewswire)
Mar-26-24 09:02PM	Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections (GuruFocus.com)
01:53PM	THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023 (InvestorPlace)
08:05AM	Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:00PM	Loading…
Feb-26-24 04:00PM	Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update (GlobeNewswire)
Dec-29-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice (Zacks)
Dec-08-23 01:05PM	Insider Sell Alert: Third Harmonic Bio Inc's Julie Person Divests 12,863 Shares (GuruFocus.com) +5.40%
Nov-09-23 09:30AM	Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ... (GuruFocus.com)
08:30AM	Third Harmonic Bio Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 08:30AM	Third Harmonic Bio Announces Leadership Changes (GlobeNewswire) -9.22%
Aug-31-23 08:30AM	Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:10AM	Third Harmonic Bio Announces Second Quarter 2023 Financial Results (GlobeNewswire) -7.00%
Jul-26-23 09:40AM	Target downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly) +9.11%
08:30AM	Loading…
Jul-25-23 08:30AM	Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 (GlobeNewswire) +5.26%
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-24-23 11:02AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
May-11-23 05:00PM	Third Harmonic Bio Announces First Quarter 2023 Financial Results (GlobeNewswire) -7.32%
Mar-29-23 08:05AM	Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire)
Dec-23-22 06:32AM	Daily Vickers Top Buyers & Sellers for 12/23/2022 (Argus Research)
Dec-22-22 05:41AM	The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug (American City Business Journals)
Dec-15-22 10:10AM	Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns (Benzinga) -78.28%
09:53AM	Third Harmonic Plunges Almost 80% After Ending Study for Skin-Inflammation Drug (Bloomberg)
08:49AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
08:22AM	Third Harmonic's stock falls 75% after discontinuing clinical trial (MarketWatch)
07:00AM	Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria (GlobeNewswire)
Nov-21-22 04:05PM	Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-22 04:15PM	Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:01AM	These Bases, Breakouts And Buy Zones Offer Fresh Opportunities (Investor's Business Daily) -6.14%
04:10PM	Loading…
Sep-19-22 04:10PM	Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.56%
Sep-15-22 11:41AM	Third Harmonic Bio stock opens more than 20% above IPO price (MarketWatch)
07:58AM	Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range (MarketWatch)

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holles Natalie C.	CEO	Apr 11 '24	Option Exercise	4.20	13,558	56,944	1,232,394	Apr 15 04:14 PM
Holles Natalie C.	CEO	Apr 11 '24	Sale	12.19	13,558	165,214	1,218,836	Apr 15 04:14 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Option Exercise	4.20	1,107	4,649	1,107	Apr 08 05:21 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Sale	10.00	1,107	11,070	0	Apr 08 05:21 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Option Exercise	4.20	12,863	54,025	12,863	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Option Exercise	4.20	4,790	20,118	4,790	Dec 07 04:03 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Sale	10.30	12,863	132,484	0	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Sale	10.03	4,790	48,062	0	Dec 07 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

THRD

Third Harmonic Bio Inc

Upgrade your FINVIZ experience